Shots:

• The approval is based on P-III PRONTO-T1D and PRONTO-T2D studies assessing Lyumjev (insulin lispro-aabc injection- 100 units/mL) and Humalog (insulin lispro injection- 100 units/mL)- both in combination with either insulin glargine or insulin degludec in adults with T1D and T2D- respectively
• Both the studies resulted in meeting its 1EPs of non-inferior A1C reduction @26wks.- when both the therapies dosed at mealtime- Lyumjev demonstrated a superior reduction in blood glucose spikes at both 1hr. & 2hrs. after a test meal- safety & tolerability profile is similar for both
• Lyumjev is a novel formulation of insulin lispro- developed to speed the absorption of insulin into the bloodstream and reduce A1C levels and is contraindicated during episodes of hypoglycemia and in patients with hypersensitivity to insulin lispro or one of the excipients in Lyumjev

Ref: Eli Lilly | Image: Eli Lilly